
Bone marrow samples from children with acute lymphoblastic leukemia (ALL) were obtained at diagnosis (BM Pre-TX) and one day post-treatment (BM Post-TX) with mercaptopurine (MP) or high-dose methotrexate (HDMTX) given alone, or mercaptopurine in combination with either low-dose MTX (LDMTX+MP) or high-dose MTX (HDMTX+MP).
(a) The study included 60 pediatric patients with newly diagnosed ALL randomized to one of four initial treatments (“training set”). (b) Additionally, 17 new patients from the current protocol were included as an independent “test set”.
| (a) treatment | n (n=60) | age at diagnosis (median in years) |
sex | race | lineage | DNA ploidy | molecular translocations |
| MP | 12 | 6.8 | male: 7 female: 5 |
white: 10 black: 2 other: 0 |
B: 8 T: 4 |
hyperdiploid: 1 other: 11 |
MLL: 1 E2A-PBX: 0 TEL-AML: 1 BCR-ABL: 0 ND2: 10 |
| HDMTX | 22 | 6 | male: 14 female: 8 |
white: 19 black: 1 other: 2 |
B: 19 T: 3 |
hyperdiploid: 4 other: 18 |
MLL: 0 E2A-PBX: 2 TEL-AML: 9 BCR-ABL: 0 ND2: 11 |
| HDMTX+MP | 10 | 5 | male: 5 female: 5 |
white: 8 black: 1 other: 1 |
B: 8 T: 2 |
hyperdiploid: 0 other: 10 |
MLL: 2 E2A-PBX: 1 TEL-AML: 3 BCR-ABL: 0 ND2:4 |
| LDMTX+MP | 16 | 6.1 | male: 13 female: 3 |
white: 12 black: 1 other: 3 |
B: 13 T: 3 |
hyperdiploid: 2 other: 14 |
MLL: 0 E2A-PBX: 0 TEL-AML: 4 BCR-ABL: 0 ND2: 12 |
| P value1 | P=0.726 | P=0.390 | P=0.665 | P=0.552 | P=0.643 | P=0.120 |
| (b) treatment | n (n=17) | age at diagnosis (median in years) |
sex | race | lineage | DNA ploidy | molecular translocations |
| HDMTX | 17 | 5 | male: 11 female: 6 |
white: 8 black: 5 other: 4 |
B: 13 T: 4 |
hyperdiploid: 8 other: 9 |
MLL: 0 E2A-PBX: 0 TEL-AML: 2 BCR-ABL: 1 ND2: 14 |
1P value determined by Fisher’s exact test except Age by Wilcoxon’s rank sum test. 2ND=none detected